Please login to the form below

Not currently logged in


This page shows the latest Zejula news and features for those working in and with pharma, biotech and healthcare.

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

CHMP backs AZ’s Lynparza for ovarian cancer maintenance

in the face of competition from newer market entrants Rubraca (rucaparib) from Clovis Oncology and Johnson &Johnson/Tesaro’s Zejula (niraparib). ... Zejula was approved for ovarian cancer maintenance last year, while Rubraca is also in late-stage

Latest news

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....